Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc > Very good Q

<< Previous

Bullboard Posts

Next >>

Comment by Rsoleblockaon Nov 12, 2022 12:52am

207 Views

Post# 35093254

RE:Very good Q

Nice synopsis, I almost sold today at 3.70 but could not pull the trigger. As longs as they do not buy something for the sake of doing so I am still comfortable with this holding.

Cheers

<< Previous

Bullboard Posts

Next >>

Cybin launches new program phase to treat Major Depressive Disorder